| * PRE-CLINICAL ASSESSMENT OF TRASTUZUMAB AND A NOVEL HDACI COMBINATION THERAPY IN THE TREATMENT OF HER-2 OVER-EXPRESSING BREAST CANCERS: BS05 M Medon, N Haynes, P Atadja, M Smyth, M Henderson, R Johnstone Anz Journal of Surgery 82, 2012 | | 2012 |
| 14 HDAC Inhibitors P Kwon, M Hsu, D Cohen, P Atadja Histone Deacetylases: Transcriptional Regulation and Other Cellular …, 2007 | | 2007 |
| 193 Histone deacetylase inhibitors LAQ824 and LBH589 inhibit proliferation and modulate angiogenesis-related genes in human endothelial cells D Qian, P Atadja, R Pili EJC Supplements 8 (2), 60, 2004 | 2 | 2004 |
| 251 Histone deacetylase inhibition—a promising anticancer therapeutic strategy P Atadja, M Hsu, P Kwon, R Pili, K Bhalla, A Wood EJC Supplements 8 (2), 78, 2004 | 1 | 2004 |
| 584 POSTER Histone deacetylase inhibitors abrogate the levels and activity of estrogen receptor (ER) α and histone deacetylase (HDAC) 6 in human breast cancer cells (BCCs) W Fiskus, A Mohapatra, P Bali, M Balasis, R Rao, P Atadja, J Wu, K Bhalla EJC Supplements 12 (4), 177, 2006 | | 2006 |
| 701 POSTER Phase I study of oral LBH589 in advanced solid tumours and non-Hodgkin's lymphoma HM Prince, D George, A Patnick, M Mita, P Atadja, M Dugan, D Butterfoss, ... EJC Supplements 4 (5), 107, 2007 | | 2007 |
| 702 POSTER Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589 S Sharma, NJ Vogelzang, J Beck, A Patnaik, M Mita, M Dugan, A Hwang, ... EJC Supplements 4 (5), 107-108, 2007 | 1 | 2007 |
| 7054 POSTER Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in … L Ellis, K Lehet, S Ramakrishnan, KM Miles, D Wang, S Liu, P Atadja, ... European Journal of Cancer, S501, 2011 | | 2011 |
| A combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 is highly active against human AML cells with constitutively active mutant FLT-3 … KN Bhalla, P Bali, P George, J Tao, F Guo, C Sigua, A Vishvanath, ... CLINICAL CANCER RESEARCH 9 (16), 6233S-6234S, 2003 | | 2003 |
| A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 … KN Bhalla, P George, R Gutti, P Bali, J Tao, F Guo, C Sigua, Y Li, P Cohen, ... Journal of Clinical Oncology 22 (14_suppl), 6541-6541, 2004 | 3 | 2004 |
| A combination of histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively active mutant FLT-3 … R Gutti, P George, P Bali, J Tao, F Guo, C Sigua, Y Li, L Moscinski, ... Cancer Research 64 (7_Supplement), 699-699, 2004 | 3 | 2004 |
| A combination of historic deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 is highly active against human AML cells with constitutively active mutant FLT-3 … P Bali, P George, JG Tao, F Guo, C Sigua, A Vishvanath, R Gutti, YQ Li, ... Blood 102 (11), 96A-97A, 2003 | 2 | 2003 |
| A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL J Symanowski, N Vogelzang, L Zawel, P Atadja, H Pass, S Sharma Journal of Thoracic Oncology 4 (2), 149-160, 2009 | 47 | 2009 |
| A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC) DE Rathkopf, BY Wong, RW Ross, DJ George, J Picus, E Tanaka, Y Chen, ... Journal of Clinical Oncology 26 (15_suppl), 5152-5152, 2008 | 13 | 2008 |
| A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors EK Rowinsky, S Pacey, A Patnaik, A O'Donnell, MM Mita, P Atadja, ... Journal of Clinical Oncology 22 (14_suppl), 3022-3022, 2004 | 22 | 2004 |
| A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies OG Ottmann, DJ Deangelo, RM Stone, H Pfeifer, B Lowenberg, P Atadja, ... Journal of Clinical Oncology 22 (14_suppl), 3024-3024, 2004 | 25 | 2004 |
| A potent, selective and cell‐active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) HÜ Kaniskan, MM Szewczyk, Z Yu, MS Eram, X Yang, K Schmidt, X Luo, ... Angewandte Chemie 127 (17), 5255-5259, 2015 | 116 | 2015 |
| A rapid method for in vivo evaluation of histone deacetylase inhibitors for efficacy and oral bioavailability using a reporter cell line in hollow fibers. PT Lassota, E Sorensen, W Yang, P Atadja, L Sambucetti, H Walker, ... CLINICAL CANCER RESEARCH 7 (11), 3705S-3705S, 2001 | | 2001 |
| Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation C Yu, BB Friday, JP Lai, A McCollum, P Atadja, LR Roberts, AA Adjei Clinical cancer research 13 (4), 1140-1148, 2007 | 97 | 2007 |
| Absolute Quantification of Histone PTM Marks by MRM-Based LC J Gao, R Liao, Y Yu, H Zhai, Y Wang, R Sack, AHFM Peters, J Chen, ... | | 2014 |
